Rafferty Asset Management LLC Has $2.46 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Rafferty Asset Management LLC lowered its holdings in ADMA Biologics, Inc. (NASDAQ:ADMAFree Report) by 13.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 544,349 shares of the biotechnology company’s stock after selling 81,147 shares during the quarter. Rafferty Asset Management LLC owned 0.24% of ADMA Biologics worth $2,460,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ADMA. Charles Schwab Investment Management Inc. increased its position in ADMA Biologics by 182.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,609,346 shares of the biotechnology company’s stock worth $5,761,000 after acquiring an additional 1,039,893 shares during the period. Walleye Capital LLC bought a new position in shares of ADMA Biologics during the 3rd quarter worth about $3,318,000. Peregrine Capital Management LLC acquired a new position in shares of ADMA Biologics during the fourth quarter valued at about $3,991,000. American Century Companies Inc. lifted its stake in shares of ADMA Biologics by 20.8% in the third quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after buying an additional 840,761 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its position in ADMA Biologics by 15.1% during the third quarter. Adage Capital Partners GP L.L.C. now owns 3,767,558 shares of the biotechnology company’s stock worth $13,488,000 after buying an additional 493,000 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on ADMA. Cantor Fitzgerald upped their price target on ADMA Biologics from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, May 10th. HC Wainwright upped their target price on ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Raymond James lifted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. Finally, Mizuho increased their price objective on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $10.50.

Check Out Our Latest Stock Analysis on ADMA

Insider Buying and Selling at ADMA Biologics

In other news, Director Steve Elms sold 49,887 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $6.01, for a total transaction of $299,820.87. Following the completion of the sale, the director now owns 2,527,500 shares of the company’s stock, valued at $15,190,275. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 639,895 shares of company stock worth $3,927,169 over the last ninety days. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Trading Down 1.0 %

Shares of ADMA opened at $10.47 on Monday. The stock has a 50 day simple moving average of $7.74 and a 200-day simple moving average of $5.99. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91. The stock has a market cap of $2.43 billion, a PE ratio of -523.50 and a beta of 0.48. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $10.85.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.03. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The company had revenue of $81.90 million during the quarter, compared to analysts’ expectations of $77.28 million. During the same period last year, the business earned ($0.03) earnings per share. The business’s revenue was up 43.9% on a year-over-year basis. On average, sell-side analysts predict that ADMA Biologics, Inc. will post 0.35 EPS for the current fiscal year.

About ADMA Biologics

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

See Also

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.